Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

January 2017

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.

Soliqua is the first insulin/GLP-1 agonist combo to hit shelves. It contains Lantus (insulin glargine U-100) plus Adlyxin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Recommend Limiting Dose and Duration of NSAIDs in High-CV-Risk Patients
Opioids Be Ready to Help More Patients Use Buprenorphine/Naloxone
Acne Know When to Recommend New OTC Differin 0.1% Gel for Acne
Diabetes Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds
Vaccines Explain Why Women Should Get Pertussis Vaccine With Every Pregnancy
Inhalers Prevent Common Inhaler Errors
Calcium Help Patients Use Calcium Supplements Safely
Pediatrics Suggest Systemic Quinolones Only Rarely in Kids...But Not Due to Joint Concerns
Dehydration Consider Diluted Apple Juice an Option for Mild Dehydration in Kids
End-of-Life Care Provide Options to Enhance End-of-Life Care
Obesity & Weight Loss Explain How Lomaira and Belviq XR Stack Up Against Other Weight Loss Meds
Practice Jardiance (empagliflozin) improving CV outcomes
Insurance Prioritize Urgent Prior Auth Requests to Avoid Gaps in Therapy